{{Drugbox
| Verifiedfields =
| verifiedrevid =
| IUPAC_name = 2-({[2-(4-bromo-2,5-dimethoxyphenyl)ethyl]amino}methyl)phenol
| image = 25B-NBOH_structure.png

<!--Clinical data-->
| tradename = 
| legal_UK = Class A

<!--Identifiers-->
| CAS_number_Ref =
| CAS_number = 1335331-46-8
| PubChem =
| ChemSpiderID_Ref =
| ChemSpiderID      = 58191433

<!--Chemical data-->
| C=17 | H=20 | Br=1 | N=1 | O=3
| molecular_weight = 365.06 g/mol
| smiles = BrC2=CC(=C(CCNCC1=C(C=CC=C1)O)C=C2OC)OC
| StdInChI_Ref =
| StdInChI = 1S/C17H20BrNO3/c1-21-16-10-14(18)17(22-2)9-12(16)7-8-19-11-13-5-3-4-6-15(13)20/h3-6,9-10,19-20H,7-8,11H2,1-2H3
| StdInChIKey_Ref =
| StdInChIKey = RSUNJYKZRKIBNB-UHFFFAOYSA-N
}}

'''25B-NBOH''' ('''2C-B-NBOH''', '''NBOH-2C-B''') is a derivative of the phenethylamine derived hallucinogen [[2C-B]] which has been sold as a [[designer drug]]. It acts as a potent [[serotonin receptor]] [[agonist]] with similar affinity to the better-known compound [[25B-NBOMe]] at [[5-HT2A receptor|5-HT<sub>2A</sub>]] and [[5-HT2C receptor|5-HT<sub>2C</sub>]] receptors with pK<sub>i</sub>s values of 8.3 and 9.4, respectively.<ref>{{cite web | url=http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000001221 | title=Synthese und Pharmakologie potenter 5-HT<sub>2A</sub>-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur | publisher=Freie Universität Berlin | date=19 March 2004 | accessdate=27 June 2015 | author=Heim, Ralf}}</ref><ref>{{Cite journal | last1 = Hansen | first1 = M. | last2 = Phonekeo | first2 = K. | last3 = Paine | first3 = J. S. | last4 = Leth-Petersen | first4 = S. | last5 = Begtrup | first5 = M. | last6 = Bräuner-Osborne | first6 = H. | last7 = Kristensen | first7 = J. L. | doi = 10.1021/cn400216u | title = Synthesis and Structure-Activity Relationships of N-Benzyl Phenethylamines as 5-HT<sub>2A/2C</sub> Agonists | journal = ACS Chemical Neuroscience | volume = 5 | issue = 3 | pages = 243–9  | year = 2014 | pmid = 24397362| pmc = 3963123}}</ref><ref>{{cite web | url=https://nru.dk/downloads/phd-theses/LisbethMarner-MolecularBrainImaging.pdf | title=Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain. | publisher=University of Copenhagen | date=2011 | accessdate=27 June 2015 | author=Martin Hansen}}</ref><ref>{{Cite journal | last1 = Ettrup | first1 = A. | last2 = Hansen | first2 = M. | last3 = Santini | first3 = M. A. | last4 = Paine | first4 = J. | last5 = Gillings | first5 = N. | last6 = Palner | first6 = M. | last7 = Lehel | first7 = S. | last8 = Herth | first8 = M. M. | last9 = Madsen | first9 = J.  | title = Radiosynthesis and in vivo evaluation of a series of substituted <sup>11</sup>C-phenethylamines as 5-HT<sub>2A</sub> agonist PET tracers | journal = European Journal of Nuclear Medicine and Molecular Imaging | year = 2010 | volume = 38 | issue = 4 | pages = 681–693 | doi = 10.1007/s00259-010-1686-8 | pmid = 21174090 }}</ref><ref name="pmid21088982">{{cite journal |author1=Silva, M. E. |author2=Heim, R. |author3=Strasser, A. |author4=Elz, S. |author5=Dove, S. | title = Theoretical studies on the interaction of partial agonists with the 5-HT<sub>2A</sub> receptor | journal = Journal of Computer-aided Molecular Design | year = 2011 | volume = 25 | issue = 1 | pages = 51–66 | pmid = 21088982 | doi = 10.1007/s10822-010-9400-2 }}</ref><ref>{{cite journal | last1 = Braden | first1 = M. R. | last2 = Parrish | first2 = J. C. | last3 = Naylor | first3 = J. C. | last4 = Nichols | first4 = D. E. | title = Molecular interaction of serotonin 5-HT2A receptor residues Phe<sub>339</sub><sup>6.51</sup> and Phe<sub>340</sub><sup>6.52</sup> with superpotent N-benzyl phenethylamine agonists | journal = Molecular Pharmacology | year = 2006 | volume = 70 | issue = 6 | pages = 1956–1964 | pmid = 17000863 | doi = 10.1124/mol.106.028720 | url = http://molpharm.aspetjournals.org/content/70/6/1956.long }}</ref>

== Legal status ==

===Sweden===
[[Riksdag|The Riksdag]] added 25B-NBOH to [[:sv:Narkotikastrafflagen|Narcotic Drugs Punishments Act]] under ''swedish schedule I'' (''"substances, plant materials and fungi which normally do not have medical use"'') as of January 26, 2016, published by [[Medical Products Agency (Sweden)|Medical Products Agency (MPA)]] in regulation ''HSLF-FS 2015:35'' listed as '''25B-NBOH''', and '''2-([2-(4-bromo-2,5-dimetoxifenyl)etylamino]metyl)fenol'''.<ref>https://lakemedelsverket.se/upload/lvfs/HSLF-FS/HSLFS-FS_2015_35.pdf</ref>

===United Kingdom===
{{N-benzylphenethylamine-Legality-United Kingdom}}

===Analogues and derivatives===
{{2C-B analogues and derivatives}}

==References==
{{Reflist}}

{{Hallucinogens}}
{{Serotonin receptor modulators}}
{{Phenethylamines}}

[[Category:25-NB (psychedelics)]]
[[Category:Designer drugs]]
[[Category:Bromoarenes]]


{{hallucinogen-stub}}